Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses.

Oncoimmunology

Fotaki G, Jin C, Ramachandran M, Kerzeli IK, Karlsson-Parra A, Yu D, Essand M.
PMID: 29399392
Oncoimmunology. 2017 Nov 27;7(3):e1395126. doi: 10.1080/2162402X.2017.1395126. eCollection 2018.

Accumulating evidence support an important role for endogenous bystander dendritic cells (DCs) in the efficiency of autologous patient-derived DC-vaccines, as bystander DCs take up material from vaccine-DCs, migrate to draining lymph node and initiate antitumor T-cell responses. We examined...

Cite
Fotaki G, Jin C, Ramachandran M, et al. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology. 2017;7(3):e1395126doi: 10.1080/2162402X.2017.1395126.
Fotaki, G., Jin, C., Ramachandran, M., Kerzeli, I. K., Karlsson-Parra, A., Yu, D., & Essand, M. (2018). Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology, 7(3), e1395126. https://doi.org/10.1080/2162402X.2017.1395126
Fotaki, Grammatiki, et al. "Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses." Oncoimmunology vol. 7,3 (2018): e1395126. doi: https://doi.org/10.1080/2162402X.2017.1395126
Fotaki G, Jin C, Ramachandran M, Kerzeli IK, Karlsson-Parra A, Yu D, Essand M. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology. 2017 Nov 27;7(3):e1395126. doi: 10.1080/2162402X.2017.1395126. eCollection 2018. PMID: 29399392; PMCID: PMC5790348.
Copy Download .nbib Format: NLM
Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma.

Frontiers in oncology

Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P.
PMID: 30719425
Front Oncol. 2019 Jan 21;9:19. doi: 10.3389/fonc.2019.00019. eCollection 2019.

Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and...

Cite
Rizell M, Sternby Eilard M, Andersson M, et al. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019;9:19doi: 10.3389/fonc.2019.00019.
Rizell, M., Sternby Eilard, M., Andersson, M., Andersson, B., Karlsson-Parra, A., & Suenaert, P. (2019). Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Frontiers in oncology, 919. https://doi.org/10.3389/fonc.2019.00019
Rizell, Magnus, et al. "Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma." Frontiers in oncology vol. 9 (2019): 19. doi: https://doi.org/10.3389/fonc.2019.00019
Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019 Jan 21;9:19. doi: 10.3389/fonc.2019.00019. eCollection 2019. PMID: 30719425; PMCID: PMC6348253.
Copy Download .nbib Format: NLM
Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.

Oncoimmunology

Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M.
PMID: 29399398
Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018.

Autologous patient-derived dendritic cells (DCs) modified

Cite
Fotaki G, Jin C, Kerzeli IK, et al. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology. 2017;7(3):e1397250doi: 10.1080/2162402X.2017.1397250.
Fotaki, G., Jin, C., Kerzeli, I. K., Ramachandran, M., Martikainen, M. M., Karlsson-Parra, A., Yu, D., & Essand, M. (2018). Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology, 7(3), e1397250. https://doi.org/10.1080/2162402X.2017.1397250
Fotaki, Grammatiki, et al. "Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models." Oncoimmunology vol. 7,3 (2018): e1397250. doi: https://doi.org/10.1080/2162402X.2017.1397250
Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018. PMID: 29399398; PMCID: PMC5790347.
Copy Download .nbib Format: NLM
Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade.

Cells

Zuo H, van Lierop MC, Kaspers J, Bos R, Reurs A, Sarkar S, Konry T, Kamermans A, Kooij G, de Vries HE, de Gruijl TD, Karlsson-Parra A, Manting EH, Kruisbeek AM, Singh SK.
PMID: 34831455
Cells. 2021 Nov 19;10(11). doi: 10.3390/cells10113233.

DCP-001 is a cell-based cancer vaccine generated by differentiation and maturation of cells from the human DCOne myeloid leukemic cell line. This results in a vaccine comprising a broad array of endogenous tumor antigens combined with a mature dendritic...

Cite
Zuo H, van Lierop MC, Kaspers J, et al. Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. Cells. 2021;10(11)doi: 10.3390/cells10113233.
Zuo, H., van Lierop, M. C., Kaspers, J., Bos, R., Reurs, A., Sarkar, S., Konry, T., Kamermans, A., Kooij, G., de Vries, H. E., de Gruijl, T. D., Karlsson-Parra, A., Manting, E. H., Kruisbeek, A. M., & Singh, S. K. (2021). Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. Cells, 10(11), . https://doi.org/10.3390/cells10113233
Zuo, Haoxiao, et al. "Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade." Cells vol. 10,11 (2021). doi: https://doi.org/10.3390/cells10113233
Zuo H, van Lierop MC, Kaspers J, Bos R, Reurs A, Sarkar S, Konry T, Kamermans A, Kooij G, de Vries HE, de Gruijl TD, Karlsson-Parra A, Manting EH, Kruisbeek AM, Singh SK. Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. Cells. 2021 Nov 19;10(11). doi: 10.3390/cells10113233. PMID: 34831455; PMCID: PMC8625408.
Copy Download .nbib Format: NLM
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors.

Molecular therapy. Methods & clinical development

Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M.
PMID: 26015949
Mol Ther Methods Clin Dev. 2014 Mar 05;1:14001. doi: 10.1038/mtm.2014.1. eCollection 2014.

Adoptive T-cell therapy of cancer is a treatment strategy where T cells are isolated, activated, in some cases engineered, and expanded ex vivo before being reinfused to the patient. The most commonly used T-cell expansion methods are either anti-CD3/CD28...

Cite
Jin C, Yu D, Hillerdal V, et al. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev. 2014;1:14001doi: 10.1038/mtm.2014.1.
Jin, C., Yu, D., Hillerdal, V., Wallgren, A., Karlsson-Parra, A., & Essand, M. (2014). Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Molecular therapy. Methods & clinical development, 114001. https://doi.org/10.1038/mtm.2014.1
Jin, Chuan, et al. "Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors." Molecular therapy. Methods & clinical development vol. 1 (2014): 14001. doi: https://doi.org/10.1038/mtm.2014.1
Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev. 2014 Mar 05;1:14001. doi: 10.1038/mtm.2014.1. eCollection 2014. PMID: 26015949; PMCID: PMC4362340.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries